Japan Biopharma Marketing feedback: investors are warming up to Daiichi Sankyo Datroway‘s Avanzar readout

Research evidence excerpt

Japan Biopharma Marketing feedback: investors are warming up to Daiichi Sankyo Datroway‘s Avanzar readout

7 July 2026

Japan Biopharma

Japan Biopharma Marketing feedback: investors are warming up

to Daiichi Sankyo Datroway's Avanzar readout

Many investors agree it is time to look beyond technology, with healthcare and Miki Sogi, Ph.D.

+81 3 6777 6991 pharma emerging as a key area of interest. Generalist investors increasingly believe the

miki.sogi@bernsteinsg.com tech cycle may be approaching a peak, even if timing remains uncertain, and are turning

to healthcare given the sector’s recent underperformance. At the same time, healthcare

Tian Tan specialists are seeking geographic diversification beyond the US, EU, and China, with

+81 3 6777 6976

tian.tan@bernsteinsg.com growing interest in Japanese biopharma.

Daiichi Sankyo: Investor sentiment on Datroway’s Avanzar has turned more constructive,

supported by a clearer understanding of Trop2 biology and QCS. Views on Datroway versus

sac TMT in 1L NSCLC remain inconclusive. Separately, concerns around management

quality continue to be widely cited.

Chugai: Investors remain broadly optimistic on Foundayo, with expectations for a launch

trajectory to strengthen in 2H driven by Medicare coverage and Lilly’s direct-to-consumer

push. Meanwhile, concerns around a potential pipeline gap are increasingly acknowledged.

Takeda: Key pipeline assets remain underappreciated. There is a notable divergence in

sentiment on IBI363 (PD-1/IL-2α bias), with strong interest among Hong Kong investors

but limited awareness ex-HK. For zasocitinib (TYK2), investors are generally familiar with

psoriasis competition but have yet to fully consider the IBD opportunity. Interest in orexin